GBA Key2Compliance has published a new white paper titled Photobiomodulation (PBM) Across Wellness and Red-Light Therapy Markets – From Product Definition to Scalable Market Access.
The paper addresses the rapid growth of PBM-based red-light therapy products across wellness, performance, aesthetic and longevity markets, and the strategic challenges that emerge as these markets mature.
Rather than focusing on regulatory compliance in isolation, the white paper presents a structured, business-oriented perspective on how intended purpose, claims, documentation, quality systems and clinical evaluation function as interconnected elements of a coherent product framework.
It highlights how misalignment between these elements often becomes a limiting factor during market expansion, partnerships or increased regulatory scrutiny.
Particular attention is given to the EU Medical Device Regulation (MDR) and Annex XVI, clarifying how regulatory relevance is determined by intended purpose and biological effect rather than technology alone. Through practical scenarios and strategic insights, the paper demonstrates how early product clarity enables flexibility, credibility and long-term growth.
The publication is intended for brand owners, manufacturers and decision-makers seeking to build sustainable market access for PBM-based red-light therapy products while retaining strategic options as expectations evolve.